Study #2021-1065
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fluvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a
MD Anderson Study Status
Not Accepting
Treatment Agent
Abemaciclib, Fulvestrant, Placebo
Description
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Neoplasm, Neoplasm Metastasis
Study phase:
Phase III
Physician name:
Rachel Layman
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-888-912-0153
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.